Shorts

PrEP access for minority populations is still a major problem
1:06
PrEP access for minority populations is still a major problem
3 days ago
by
Logan Lutton
AI shows promise in early melanoma detection but real-world trials still needed
1:15
AI shows promise in early melanoma detection but real-world trials still needed
9 days ago
by
Briana Contreras
Botulinum toxin injections may reduce depression
0:46
Botulinum toxin injections may reduce depression
16 days ago
by
Logan Lutton
Collaborating across community services to address behavioral health needs
1:15
Collaborating across community services to address behavioral health needs
23 days ago
by
Briana Contreras
Aging with HIV could mean isolation, survivor's guilt
1:03
Aging with HIV could mean isolation, survivor's guilt
25 days ago
by
Logan Lutton
Eye Imaging Emerges Ophthalmology a Leader in AI | AAO 2025
1:05
Eye Imaging Emerges Ophthalmology a Leader in AI | AAO 2025
a month ago
by
Briana Contreras
Real-World Data Suggests Longer-Lasting Benefits With Aflibercept 8 mg
0:40
Real-World Data Suggests Longer-Lasting Benefits With Aflibercept 8 mg
2 months ago
by
Briana Contreras
Reducing Health System Readmissions with AI
0:56
Reducing Health System Readmissions with AI
2 months ago
by
Logan Lutton
Florida Law Sparks ERISA Compliance Questions for Employers
1:10
Florida Law Sparks ERISA Compliance Questions for Employers
2 months ago
by
Briana Contreras
Navitus Exec Warns State PBM Laws Could Limit Patient Access
0:40
Navitus Exec Warns State PBM Laws Could Limit Patient Access
2 months ago
by
Briana Contreras



Manage Your Email Preferences

To ensure you're receiving the most relevant communications, please let us know which types of emails you'd like to get from us. This quick survey helps us tailor our messages to your interests.

Manage Your Email Preferences

Check Out Our November Issue!

In this month's cover story we highlight how drugmakers are scrambling to set up direct-to-consumer programs in response to President Donald Trump’s executive orders. Should pharmacy benefit managers be worried? Are the programs good for patients?

Check Out Our November Issue!

Have you subscribed to our complimentary e-newsletter yet? Don’t fall behind in 2025! Get the latest industry news, event updates, and more from Managed Healthcare Executive®. Sign up here!

#MostFavoredNation webinar series

Part 3 of our #MostFavoredNation webinar series is now available on demand.

 #MostFavoredNation webinar series

Continuing Medical Education


All News

cut-stock@adobe.com, AI generated

Kamuvudines are a new class of drugs that are derived from the anti-HIV nucleoside reverse transcriptase inhibitors. They are designed to inhibit the inflammasome, part of the innate immune system that is triggered in geographic atrophy.